Description

IVERLAST 12 MG

Indications

IVERLAST 12 MG is primarily indicated for the treatment of various parasitic infections, including but not limited to strongyloidiasis and onchocerciasis. It is also used as an adjunct therapy in certain cases of scabies and other ectoparasitic infestations. The active ingredient, ivermectin, has shown efficacy against a wide range of parasitic organisms, making it a valuable option in the management of these conditions.

Mechanism of Action

IVERLAST 12 MG contains ivermectin, which is a macrocyclic lactone derived from the fermentation of the soil bacterium Streptomyces avermitilis. The drug works by binding to specific chloride channels in the nerve and muscle cells of parasites. This binding leads to an increase in permeability of the cell membrane to chloride ions, resulting in paralysis and death of the parasites. Additionally, ivermectin enhances the release of gamma-aminobutyric acid (GABA), a neurotransmitter that further contributes to the paralysis of the parasites, effectively eliminating them from the host.

Pharmacological Properties

IVERLAST 12 MG exhibits a broad spectrum of activity against a variety of nematodes and arthropods. It is well-absorbed after oral administration, with peak plasma concentrations typically occurring within 4 hours. The drug is extensively distributed throughout the body tissues and has a half-life of approximately 18 hours. Ivermectin undergoes hepatic metabolism, primarily through cytochrome P450 enzymes, and is excreted mainly in the feces. Its pharmacokinetic profile allows for once-daily dosing in most cases, enhancing patient compliance.

Contraindications

IVERLAST 12 MG is contraindicated in individuals with a known hypersensitivity to ivermectin or any of the excipients present in the formulation. It should also be avoided in patients with severe liver impairment, as this may affect the metabolism and clearance of the drug. Additionally, caution is advised when considering treatment in patients with a history of meningitis or in those who are pregnant or breastfeeding, as the safety of ivermectin in these populations has not been fully established.

Side Effects

Common side effects associated with the use of IVERLAST 12 MG may include dizziness, nausea, diarrhea, and abdominal pain. Some patients may experience more severe reactions such as hypotension, tachycardia, or allergic reactions, including rash and pruritus. In rare cases, neurological effects such as seizures or encephalopathy may occur, particularly in patients with high parasitic loads. It is essential for patients to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of IVERLAST 12 MG varies depending on the type of infection being treated. For strongyloidiasis, the typical dose is a single oral dose of 200 micrograms per kilogram of body weight. For onchocerciasis, the dosing regimen may involve repeated doses every 6 to 12 months, depending on the severity of the infection and the patient’s response to treatment. It is crucial to follow the healthcare provider’s instructions regarding dosage and duration of therapy to ensure optimal outcomes and minimize the risk of adverse effects.

Interactions

IVERLAST 12 MG may interact with other medications, particularly those that affect hepatic metabolism. Drugs that induce cytochrome P450 enzymes can potentially decrease the effectiveness of ivermectin, while inhibitors of these enzymes may increase the risk of toxicity. It is essential for patients to inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions. Special caution should be exercised when co-administering with other antiparasitic agents or medications that have central nervous system effects.

Precautions

Before initiating treatment with IVERLAST 12 MG, it is essential to conduct a thorough medical history and physical examination. Patients with a history of liver disease, neurological disorders, or those who are immunocompromised should be monitored closely during treatment. Additionally, patients should be informed about the potential for post-treatment reactions, which may occur as a result of the death of parasites. These reactions can include fever, rash, and lymphadenopathy, and may require symptomatic management. Pregnant and breastfeeding women should discuss the risks and benefits of treatment with their healthcare provider.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of IVERLAST 12 MG in treating various parasitic infections. A study published in the Journal of Infectious Diseases showed that a single dose of ivermectin was effective in reducing the burden of Strongyloides stercoralis in endemic populations. Another clinical trial published in the American Journal of Tropical Medicine and Hygiene highlighted the effectiveness of ivermectin in reducing the prevalence of onchocerciasis in treated communities. These studies underscore the importance of IVERLAST 12 MG as a therapeutic option for managing parasitic infections.

Conclusion

IVERLAST 12 MG is a valuable medication in the treatment of various parasitic infections, particularly strongyloidiasis and onchocerciasis. Its unique mechanism of action, favorable pharmacokinetic properties, and broad spectrum of activity make it an essential tool in the fight against parasitic diseases. However, responsible use, adherence to dosing guidelines, and awareness of potential side effects and interactions are crucial for ensuring patient safety and treatment efficacy. Healthcare providers should continue to educate patients about the importance of completing the prescribed course of therapy and monitoring for any adverse effects.